(Reuters) -Australian biotech firm CSL said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its footprint in the North American country over the next five years.
The investments will strengthen CSL’s U.S. manufacturing capabilities and thereby secure the local supply chain, the company said, adding that it has invested over $3 billion into its U.S. operations since 2018.
Plasma-derived therapies form the core of the portfolio of CSL Behring, one of the company’s divisions that caters to patients with rare and serious diseases as well as those suffering from trauma-related bleeding.
Behring, which contributed to more than 70% of the group’s revenue in fiscal 2025, already operates one manufacturing facility in Kankakee, Illinois, according to CSL’s latest annual report.
CSL last month lowered its full-year revenue and profit forecasts while announcing the delay regarding the spin-off plans of its vaccine division, CSL Seqirus.
The company had initially expected to spin off Seqirus by next June but had to shelve the plans after vaccination rates in the northern hemisphere winter season were projected to fall by 12% in its key U.S. market.
(Reporting by Sneha Kumar in Bengaluru; Editing by Anil D’Silva and Shreya Biswas)
Comments